Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
复制标题
DOI:
10.2217/pgs.10.172
复制
发表时间:
2011-03
期刊:
影响因子:
2.1
通讯作者:
Peters GJ
中科院分区:
文献类型:
--
作者:
Lemos C;Giovannetti E;Zucali PA;Assaraf YG;Scheffer GL;van der Straaten T;D'Incecco A;Falcone A;Guchelaar HJ;Danesi R;Santoro A;Giaccone G;Tibaldi C;Peters GJ
The current study investigates whether or not functional polymorphisms in the ATP-binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non-small-cell lung cancer (NSCLC) patients. Towards this end, ABCG2 polymorphisms and expression were assessed in DNA and tumors from 94 NSCLC patients treated with gefitinib, whereas their associations with toxicity/response and time-to-progression/overall survival were evaluated using Pearson-χ2 and log-rank-test, respectively. Patients carrying an ABCG2 −15622T/T genotype or harboring at least one TT copy in the ABCG2 (1143C/T, −15622C/T) haplotype developed significantly more grade 2/3 diarrhea (p < 0.01). No associations were found between polymorphisms and outcome. Consistently, ABCG2 protein levels in tumors were not significantly different between patients harboring different ABCG2 variants. The ABCG2 −15622C/T polymorphism and ABCG2 (1143C/T, −15622C/T) haplotype resulted in a gefitinib-dependent, moderate-to-severe diarrhea suggesting that these pharmacogenetic markers should be considered to optimize NSCLC treatment.
登录
查看更多内容
影响因子:
158.5
作者:
Lynch, TJ;Bell, DW;Haber, DA
通讯作者:
Haber, DA
影响因子:
45.3
作者:
Peréz-Soler, R;Saltz, L
通讯作者:
Saltz, L
影响因子:
3.7
作者:
Kondo, C;Suzuki, H;Sugiyama, Y
通讯作者:
Sugiyama, Y
影响因子:
7.3
作者:
Diestra, JE;Scheffer, GL;Izquierdo, MA
通讯作者:
Izquierdo, MA
影响因子:
2.1
作者:
Keskitalo, Jenni E.;Pasanen, Marja K.;Niemi, Mikko
通讯作者:
Niemi, Mikko